FDA
-
-
-
-
-
-
-
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
-
-
-
-
-
-
-
The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients
-
-
-
-
-
-
-
Medicines Co. (MDCO) Announces New L-T Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol (Earlier)
-
-
-
-
-
-
-
The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
-
-
-
-
-
-
-
Pre-Open Movers 11/29: (PETX) (NUAN) (MLNT) Higher; (WAIR) (ADSK) (TDOC) Lower (more...)
-
-
-
-
-
-
-
Medicines Co. (MDCO) Announces FDA Approval of VABOMERE
-
-
-
-
-
-
-
The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

